A Randomized Phase 2 Trial Comparing Amrubicin Versus Topotecan as Second-Line Treatment in Patients With Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy.

Trial Profile

A Randomized Phase 2 Trial Comparing Amrubicin Versus Topotecan as Second-Line Treatment in Patients With Extensive Small Cell Lung Cancer Sensitive to First-Line Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2010

At a glance

  • Drugs Amrubicin; Topotecan
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Cabrellis Pharmaceuticals; Celgene Corporation; Pharmion Corporation
  • Most Recent Events

    • 20 Sep 2009 Results presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
    • 05 Aug 2009 Results were presented at the 13th World Conference on Lung Cancer, according to a Celgene media release.
    • 04 Aug 2009 Results have been presented at the 13th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top